Gilead Sciences, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GILD research report →
Companywww.gilead.com
Gilead Sciences, Inc. , a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases.
- CEO
- Daniel O'Day
- IPO
- 1992
- Employees
- 17,600
- HQ
- Foster City, CA, US
Price Chart
Valuation
- Market Cap
- $162.26B
- P/E
- 17.61
- P/S
- 5.46
- P/B
- 6.90
- EV/EBITDA
- 13.27
- Div Yield
- 2.44%
Profitability
- Gross Margin
- 79.35%
- Op Margin
- 38.26%
- Net Margin
- 30.99%
- ROE
- 42.20%
- ROIC
- 20.31%
Growth & Income
- Revenue
- $29.44B · 2.39%
- Net Income
- $8.51B · 1672.92%
- EPS
- $6.84 · 1700.00%
- Op Income
- $11.70B
- FCF YoY
- -8.24%
Performance & Tape
- 52W High
- $157.29
- 52W Low
- $104.46
- 50D MA
- $136.74
- 200D MA
- $128.02
- Beta
- 0.33
- Avg Volume
- 6.14M
Get TickerSpark's AI analysis on GILD
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 15, 26 | Dickinson Andrew D | sell | 3,000 |
| May 15, 26 | Mercier Johanna | other | 25,000 |
| May 15, 26 | Mercier Johanna | sell | 7,749 |
| May 15, 26 | Mercier Johanna | sell | 11,177 |
| May 15, 26 | Mercier Johanna | sell | 8,374 |
| May 15, 26 | Mercier Johanna | sell | 700 |
| May 15, 26 | Mercier Johanna | other | 25,000 |
| Apr 30, 26 | Bluestone Jeffrey | other | 1,146 |
| Apr 30, 26 | Bluestone Jeffrey | other | 4,884 |
| Apr 30, 26 | BARTON JACQUELINE K | other | 1,146 |
Our GILD Coverage
We haven't published any research on GILD yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate GILD Report →